-
Dr. Angélique VIENOT
Gastroenterologist
University Hospital of Besançonangelique.vienot@gmail.com
Main publications
Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for second-line...
Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY, Dr. Angélique VIENOT, Mme. Aurélia MEURISSE
Journal name : JNCI J Natl Cancer Inst
Latest publications
AbstractFluoropyrimidine (FP) plus platinum chemotherapy has been recently established as a second-line (L2) preferred...
Posted by : Dr. Dewi VERNEREY, Mme. Aurélia MEURISSE, Dr. Angélique VIENOT
Journal name : Int J Cancer
Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for second-line...
Posted by : Pr. Franck BONNETAIN, Dr. Dewi VERNEREY, Dr. Angélique VIENOT, Mme. Aurélia MEURISSE
Journal name : JNCI J Natl Cancer Inst
AbstractBackground: FOLFIRINOX regimen is the first-line reference chemotherapy (L1) in advanced pancreatic ductal...
Posted by : Dr. Angélique VIENOT, Dr. Dewi VERNEREY
Journal name : World J Gastrointest Oncol
AbstractBackground: Surgical resection with adjuvant chemotherapy is the only treatment that can provide long term...
Posted by : Dr. Dewi VERNEREY, , Dr. Angélique VIENOT
Journal name : Front Oncol
AbstractDocetaxel, cisplatin and 5-fluorouracil (DCF) chemotherapy regimen is highly effective in advanced anal squamous...
Posted by : Dr. Dewi VERNEREY, Dr. Angélique VIENOT, Mme. Aurélia MEURISSE
Journal name : Int J Mol Sci
Background:The management of locally advanced pancreatic cancer (LAPC) patients remains controversial. Better...
Posted by : Dr. Angélique VIENOT, Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Journal name : British Journal of Cancer
Latest tools
Currently, the management of advanced pancreatic cancer patients is complex in second-line chemotherapy according to the...
Posted by : Dr. Angélique VIENOT, Dr. Dewi VERNEREY